Deferasirox对铁质积聚有效果吗？

Iron chelators are currently the mainstream treatment for iron removal. Among them, (Deferasirox, Enriga) is easy to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment. So, does Deferasirox (Deferasirox, Enrig) ​​have an effect on iron accumulation?

A multicenter, prospective clinical trial to evaluate the safety and efficacy of Deferasirox (Deferasirox, Enrig) in patients with low- or intermediate-risk-1 myelodysplastic syndrome (MDS). The study selected patients with serum ferritin ≥1000 μg/L, transfusion dependence and red blood cell transfusions ≥20U to be included. The starting dose of Deferasirox (Deferasirox, Enrig) ​​is 20 mg/kg/d, which can be adjusted up to 40 mg/kg/d. A total of 176 patients were enrolled in the study, of whom 173 received treatment. 53% of patients completed 12 months of treatment (n = 91) with a 23% decrease in mean serum ferritin, 36.7% completed 2 years of treatment (N = 49), and 36.5% completed 3 years of treatment (N = 33).

The study found that the reduction of serum ferritin was significantly positively correlated with the improvement of ALT (P <0.001). Baseline labile plasma iron (LPI) was elevated in 68 patients (39.3%). After 13 weeks, all patients with abnormal baseline LPI levels returned to normal. According to the International Working Group's 2006 criteria, 51 patients (28%) had improved hemograms, of which only 7 patients received growth factors or MDS. During the 3-year study, 138 (79.8%) patients discontinued treatment, 43 (24.8%) of whom discontinued treatment due to adverse events or disease progression, and 23 (13.2%) due to abnormal laboratory test values. The most common drug-related adverse events were gastrointestinal disturbances and increased serum creatinine.

According to patients' feedback, Deferasirox (deferasirox, Enrig) is very effective. It plays a good auxiliary role in patients with thalassemia or other rare anemias that require long-term blood transfusions that lead to iron accumulation (people who require long-term blood transfusions (blood transfusion volume up to 100 ml/kg) and whose serum ferritin exceeds 1000 μg/L).

The above is the content of the effects of (Deferasirox, Enrego), I hope it can help you!